Search
ixazomib (Ninlaro)
Indications:
- treatment of multiple myeloma in patients who have received at least one prior therapy
- approved in combination with lenalidomide & dexamethasone
Dosage:
oral capsule: 2.3 mg, 3 mg, 4 mg
Adverse effects:
- most common
- nausea/vomiting. diarrhea, constipation
- thrombocytopenia
- peripheral neuropathy
- peripheral edema
- back pain
Mechanism of action:
- proteasome inhibitor
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=25183872
References
- FDA News Release. November 20, 2015
FDA approves Ninlaro, new oral medication to treat multiple myeloma.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473771.htm